# EXORPHIA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exorphia

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.exorphia.com
- Total disclosed funding: $2.8M
- Latest round: Seed (Apr 12, 2021)
- Investors on record: 1

## About

Based in Tokyo, Japan, and founded in 2019, EXORPHIA Inc. develops novel medicine using extracellular vesicles. As of 2023, the company is headed by its CEO Koji Guchiishi, who founded the firm too. The company offers the INPACT-EVTM platform technology to characterize, concentrate, and purify exosomes. It engages itself in the research and development, manufacture, and sale of human cell-derived exosome drugs. Exosomes are a method of delivering medications to the body. It can effectively transfer diverse functional molecules derived from cells, such as microRNAs and proteins, to their intended targets. In? August 2025, EXORPHIA Inc. raised? an undisclosed amount ?in?venture funding? from new investor Rohto Pharmaceutical. The company plans to use its proceeds from August 2025 funding to broaden its operations and enhance its corporate worth.

## Funding rounds

- Seed, Apr 12, 2021, $2.8M — D3 LLC

## Investors

- D3 LLC (https://capitalatlas.ai/funds/d3-llc) — Seed